BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

BCRX

Biocryst Pharmaceuticals Inc.
Nasdaq · Biological products, (no diagnostic substances) (SIC 2836) · FY ends 31 Dec

Revenue, quarterly

$218M+33.6% year on year
$600M$400M$200M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

97.8%+0.8 pp year on year
100%98%96%94%92%
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$155M+76.0% year on year
$600M$400M$200M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

$373M+2269.0% year on year
$400M$200M$0−$200M
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty